MORONI, FLAVIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.542
EU - Europa 10.103
AS - Asia 6.546
SA - Sud America 870
OC - Oceania 168
AF - Africa 160
Continente sconosciuto - Info sul continente non disponibili 109
Totale 36.498
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.292
RU - Federazione Russa 3.356
IT - Italia 2.034
SG - Singapore 1.910
CN - Cina 1.293
HK - Hong Kong 1.203
PL - Polonia 988
IE - Irlanda 941
SE - Svezia 941
VN - Vietnam 716
BR - Brasile 689
KR - Corea 554
DE - Germania 356
FI - Finlandia 343
FR - Francia 313
UA - Ucraina 299
TR - Turchia 249
GB - Regno Unito 212
IN - India 175
AU - Australia 168
CA - Canada 159
CH - Svizzera 147
JP - Giappone 75
JO - Giordania 68
BD - Bangladesh 61
AR - Argentina 47
IQ - Iraq 47
MX - Messico 35
NL - Olanda 35
CI - Costa d'Avorio 34
ID - Indonesia 34
ZA - Sudafrica 34
CO - Colombia 31
EC - Ecuador 31
PK - Pakistan 30
BE - Belgio 29
ES - Italia 23
SA - Arabia Saudita 21
NG - Nigeria 20
VE - Venezuela 20
PH - Filippine 18
CR - Costa Rica 16
RO - Romania 15
PE - Perù 14
PY - Paraguay 14
CL - Cile 13
BG - Bulgaria 11
SC - Seychelles 11
AT - Austria 10
EG - Egitto 10
KE - Kenya 10
MY - Malesia 10
TN - Tunisia 10
UZ - Uzbekistan 10
AZ - Azerbaigian 9
EU - Europa 9
MA - Marocco 8
PT - Portogallo 8
DK - Danimarca 7
HN - Honduras 7
LB - Libano 7
LT - Lituania 7
AE - Emirati Arabi Uniti 6
BY - Bielorussia 6
NI - Nicaragua 6
NP - Nepal 6
TW - Taiwan 6
UY - Uruguay 6
GT - Guatemala 5
SN - Senegal 5
TH - Thailandia 5
ET - Etiopia 4
IL - Israele 4
JM - Giamaica 4
OM - Oman 4
AM - Armenia 3
BO - Bolivia 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
HR - Croazia 3
HU - Ungheria 3
IR - Iran 3
KW - Kuwait 3
KZ - Kazakistan 3
NO - Norvegia 3
TT - Trinidad e Tobago 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BF - Burkina Faso 2
BJ - Benin 2
GD - Grenada 2
GP - Guadalupe 2
GY - Guiana 2
KH - Cambogia 2
LU - Lussemburgo 2
MD - Moldavia 2
PS - Palestinian Territory 2
QA - Qatar 2
SY - Repubblica araba siriana 2
Totale 36.376
Salva come PNG Salva come JPEG
Città #
Santa Clara 3.000
Fairfield 1.759
Ashburn 1.719
Singapore 1.335
Chandler 1.075
Warsaw 985
Hong Kong 979
Dublin 941
Woodbridge 802
Cambridge 716
Seattle 702
San Jose 638
Houston 630
Wilmington 613
Jacksonville 552
Seoul 548
Milan 382
Beijing 353
Buffalo 333
Ann Arbor 308
Council Bluffs 289
Los Angeles 284
Lawrence 280
Altamura 270
The Dalles 269
Princeton 264
Lauterbourg 236
Boardman 207
Rome 205
Ho Chi Minh City 197
Medford 176
Melbourne 162
Izmir 158
Hefei 156
Hanoi 153
Bern 143
Boston 142
Mumbai 116
San Diego 110
Florence 102
New York 95
Moscow 88
Dallas 87
Phoenix 87
Shanghai 84
Dong Ket 82
Munich 70
Tokyo 68
São Paulo 66
Helsinki 64
Naples 58
Norwalk 54
Bologna 52
Turin 50
Dearborn 47
Toronto 45
Chicago 42
Paris 41
Kent 40
London 37
Hillsboro 36
Da Nang 35
Abidjan 34
Palermo 33
Guangzhou 32
Verona 32
Falls Church 31
Redondo Beach 31
Columbus 30
Brussels 29
Orem 29
Frankfurt am Main 26
Brooklyn 23
Figino 23
Rio de Janeiro 23
Turku 23
West Jordan 23
Yubileyny 23
Haiphong 22
Portsmouth 21
Venice 21
Washington 21
Tianjin 20
Abuja 19
Baghdad 18
San Francisco 18
Genoa 17
Johannesburg 17
Montreal 17
Bari 16
Belo Horizonte 16
Denver 16
Frankfurt Am Main 16
Andover 15
Auburn Hills 15
Cagliari 15
Catania 15
Jakarta 15
Miano 15
Shenzhen 15
Totale 24.442
Salva come PNG Salva come JPEG
Nome #
GPR35 Activation Reduces Ca2+ Transients and Contributes to the Kynurenic Acid-Dependent Reduction of Synaptic Activity at CA3-CA1 Synapses 390
The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways. 346
Arrays of MicroLEDs and Astrocytes: Biological Amplifiers to Optogenetically Modulate Neuronal Networks Reducing Light Requirement 342
Differential role of mGlu1 and mGlu5 receptors in rat hippocampal slice models of ischemic tolerance 309
Interplay between histone acetylation/deacetylation and poly(ADPribosyl)ation in the development of ischemic tolerance in vitro 295
Group I metabotropic glutamate receptors stimulate the activity of poly(ADP-ribose) polymerase in mammalian mGlu1-transfected cells and in cortical cell cultures. 291
Glutamate Receptor-Mediated Neurotoxicity in a Model of Ethanol Dependence and Withdrawal in Rat Organotypic Hippocampal Slice Cultures 268
HCV Patients Psychopathology and Tryptophan Metabolism: Analysis of the Effects of Pegylated Interferon plus Ribavirin Treatment 264
HYDAMTIQ, a selective PARP-1 inhibitor, improves bleomycin-induced lung fibrosis by dampening the TGF-β/SMAD signalling pathway 258
Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. 249
Methadone Dose Adjustments, Plasma R-Methadone Levels and Therapeutic Outcome of Heroin Users: A Randomized Clinical Trial 249
G-protein coupled receptor 35 (GPR35) activation and inflammatory pain: Studies on the antinociceptive effects of kynurenic acid and zaprinast 247
Differential role of poly(ADP-ribose) polymerase-1 in apoptotic and necrotic neuronal death induced by mild or intense NMDA exposure in vitro 244
5-HYDROXYINDOLE CAUSES CONVULSIONS AND INCREASES TRANSMITTER RELEASE IN THE CA1 REGION OF RAT HIPPOCAMPUS 241
A key role for poly(ADP-ribose) polymerase-1 activity during human dendritic cell maturation. 237
Kynurenic acid and zaprinast induce analgesia by modulating HCN channels through GPR35 activation 231
Activation of mGlu1 but not mGlu5 metabotropic glutamate receptors contributes to post-ischemic neuronal injury in vitro and in vivo. 212
Peripheral and Splanchnic Indole and Oxindole Levels in Cirrhotic Patients: A Study on the Pathophysiology of Hepatic Encephalopathy 209
Mono-galloyl glucose derivatives are potent poly(ADP-ribose) glycohydrolase (PARG) inhibitors and partially reduce PARP-1-dependent cell death 209
Biochemical and electrophysiological studies on (S)-(+)-2-(3'- carboxybicyclo[1.1.1]pentyl)-glycine (CBPG), a novel mGlu5 receptor agonist endowed with mGlu1 receptor antagonist activity. 203
Ethanol Toxicity During Brain Development: Alterations of Excitatory Synaptic Transmission in Immature Organotypic Hippocampal Slice Cultures 203
Neurological basis of AMP-dependent thermoregulation and its relevance to central and peripheral hyperthermia. 201
Poly(ADP-ribose) polymerase-1 is a nuclear epigenetic regulator of mitochondrial DNA repair and transcription 200
Acute cyanide intoxication treated with a combination of hydroxycobalamin, sodium nitrite, and sodium thiosulfate. 200
Adenosine decreases aspartate and glutamate release from rat hippocampal slices. 199
8-phenyltheophylline potentiates the evoked electrical activity in hippocampal slices. 198
Pharmacological effects of exogenous NAD on mitochondrial bioenergetics, DNA repair, and apoptosis 197
Long-lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable inhibitors of poly(ADP-ribose) polymerase. 195
Biochemical and behavioural studies on indole-pyruvic acid: a keto-analogue of tryptophan. 193
Poly(ADP-ribose) polymerase inhibition with HYDAMTIQ reduces allergen-induced asthma-like reaction, bronchial hyper-reactivity and airway remodelling. 193
CB1 receptors and post-ischemic brain damage: studies on the toxic and neuroprotective effects of cannabinoids in rat organotypic hippocampal slices 193
PARP-1 activation causes neuronal death in the hippocampal CA1 region by increasing the expression of Ca2+-permeable AMPA receptors 193
1-Amino-1,5-dicarboxylic acid and (S)-(+)-2-(3'-carboxybicyclo[1.1.1]pentyl)-glycine, two mGlu1 receptor-preferring antagonists, reduce neuronal death in in vitro and in vivo models of cerebral ischemia 191
Selective PARP-2 inhibitors increase apoptosis in hippocampal slices but protect cortical cells in models of post-ischaemic brain damage. 191
Neurological basis of AMP-dependent thermoregulation and its relevance to central and peripheral hyperthermia 190
Kynurenic acid inhibits the release of the neurotrophic fibroblast growth factor (FGF)-1 and enhances proliferation of glia cells, in vitro. 187
Ischemic Neuroprotection by TRPV1 Receptor-Induced Hypothermia 187
Differential mechanisms of tolerance induced by NMDA and DHPG preconditioning 186
Ammonium acetate inhibits ionitropic receptors and differentially affects metabotropic receptors for glutamate 183
Histone Deacetylase (HDAC) Inhibitors Reduce the Glial Inflammatory Response In Vitro and In Vivo 182
A new endogenous anxiolytic agent: L-pyroglutamic acid. 181
Modulation of the spontaneous histamine release by adrenergic and cholinergic drugs 180
Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients 179
Rat hippocampal slice culture models for the evaluation of neuroprotective agents. 178
Mild activation of poly(ADP-ribose) polymerase (PARP) is neuroprotective in rat hippocampal slice models of ischemic tolerance 177
Sulfate esters of hydroxy amino acids as stereospecific glutamate receptor agonists. 177
Levels and synthesis of glutamate and aspartate in the olfactory cortex following bulbectomy. 176
Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis. 176
Pharmacological characterization of metabotropic glutamate receptors potentiating NMDA responses in mouse cortical wedge preparations 176
Calcium channel inhibitors suppress the morphine-withdrawal syndrome in rats. 176
Involvement of endocannabinoid signaling in the neuroprotective effects of subtype 1 metabotropic glutamate receptor antagonists in models of cerebral ischemia 174
Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities. 173
Increase in the content of quinolinic acid in cerebrospinal fluid and frontal cortex of patients with hepatic failure. 173
Carboxymethyl beta-glucan binds to corneal epithelial cells and increases cell adhesion to laminin and resistance to oxidative stress. 173
The release of endogenous GABA and glutamate from the cerebral cortex in the rat. 172
Tryptophan/kynurenine pathway changes in HCV-infected patients: possible involvement in associated neuropsychiatry pathology 172
Neuroprotection by group I mGlu receptors in a rat hippocampal slice model of cerebral ischemia is associated with the PI3K–Akt signaling pathway: A novel postconditioning strategy? 171
DHPG and NMDA preconditioning induce ischemic tolerance with differential mechanisms 171
Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages. 170
18β-glycyrrhetic acid inhibits immune activation triggered by HMGB1, a pro-inflammatory protein found in the tear fluid during conjunctivitis and blepharitis 170
Interazioni farmacologiche nella terapia moderna. Farmaci e salute 147-153, 1975. 170
Presynaptic kynurenate-sensitive receptors inhibit glutamate release. 170
IDENTIFICATION AND MEASUREMENT OF OXINDOLE (2-INDOLINONE) IN THE MAMMALIAN BRAIN AND OTHER RAT ORGANS 169
Studies on the pharmacological properties of oxindole (2-hydroxyindole) and 5-hydroxyindole: are they involved in hepatic encephalopathy? 169
1-Methyl-4-Phenylpyridinium (Mpp+) Modulates Hyperpolarization-Activated Current (Ih) In Substantia Nigra Pars Compacta Dopaminergic Neurons 169
Interplay between group I mGlu and the endocannabinoid system in the hippocampus: studies in models of cerebral ischemia 168
(+)MCPG induces PKC-epsilon translocation in cortical synaptosomes through a PLD-coupled mGluR 167
1-Aminoindan-1,5-dicarboxylic acid: a novel antagonist at phospholipase C-linked metabotropic glutamate receptors. 167
Poly (ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemia 165
General anaesthetics inhibit the responses induced by glutamate receptor agonists in the mouse cortex. 165
Poly(ADP-ribose)polymerase 1 (PARP-1) and postischemic brain damage. 165
GPR35 is functionally expressed in astrocytes and mediates kynurenic acid-dependent reduction of excitatory synaptic activity at CA3-CA1 synapse. 165
Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia. 164
Erythropoietin attenuates post-traumatic injury in organotypic hippocampal slices 163
Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool 163
Effect of cannabinoids on the turnover rate of acetylcholine in rat hippocampus, striatum and cortex. 163
In vitro cell growth inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on human tumor cell lines with defective DNA damage response pathways 162
Comet assay as a novel approach for studying DNA damage in focal cerebral ischemia: differential effects of NMDA receptor antagonists and poly(ADP-ribose) polymerase inhibitors 162
An electrophysiological study of the mGlu1 receptors ability to modulate endocannabinoids production and inhibitory synaptic transmission in the CA1 hippocampal area 161
Increase in kynurenic acid in Huntington's disease motor cortex. 160
Poly(ADP-ribose) catabolism triggers AMP-dependent mitochondrial energy failure 160
Acute changes of blood ammonia may predict short-term adverse effects of valproic acid. 160
Poly(ADP-ribosyl)ation regulates heat shock factor-1 activity and the heat shock response in murine fibroblasts 158
Tryptophan availability selectively limits NO-synthase induction in macrophages. 158
The excitotoxin quinolinic acid is present and unevenly distributed in the rat brain. 158
(2R, 1’S, 2’R, 3’S)-2-(2’-Carboxy-3’-phenylcyclopropyl)glycine (PCCG-13), the first potent and selective competitive antagonist of PLD-coupled metabotropic receptors. Asymmetric synthesis and preliminary biological reports. 157
Alteration of the subcellular and tissue distribution of ELAV-type proteins during cerebral ischemia in the rat 156
mGlu1 receptors and endocannabinoids: neuroprotection studies in an in vitro model of cerebral ischemia 156
Release of glutamate from striatum of freely moving rats by pros-methylimidazoleacetic acid 155
PARP-1 inhibition prevents CNS migration of dendritic cells during EAE, suppressing the encephalitogenic response and relapse severity 155
Pharmacological characterization of metabotropic glutamate receptors coupled to phospholipase D in the rat hippocampus 154
Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases 153
Studies on the pharmacological properties of oxindole (2-hydroxyindole) and 5-hydroxyindole: are they involved in hepatic encephalopathy? 153
The regulation of brain kynurenic acid content: focus on indole-3-pyruvic acid. 153
Erratum: The inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on growth in human tumor cell lines with defective DNA damage response pathways (Oncology Research 25:9 (1441-1451) DOI: 10.3727/096504017X14926854178616) 153
Poly(ADP-ribose) accumulation and enhancement of postischemic brain damage in 110-kDa poly(ADP-ribose) glycohydrolase null mice. 152
Kynurenine 3-mono-oxygenase inhibitors reduce glutamate concentration in the extracellular spaces of the basal ganglia but not in those of the cortex or hippocampus 151
KYNURENINE DISPOSITION IN BLOOD AND BRAIN OF MICE: EFFECTS OF SELECTIVE INHIBITORS OF KYNURENINE HYDROXYLASE AND OF KYNURENINASE 151
Tryptophan/Kynurenine pathway changes in HCV infected patients: possible involvment in associated neuropsychiathy pathology. 150
Kynurenic acid is present in the rat brain and its content increases during development and aging processes. 149
Totale 19.050
Salva come PNG Salva come JPEG
Categoria #
all - tutte 103.854
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 103.854
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.376 0 0 76 93 74 78 57 91 89 74 247 497
2022/20234.434 452 763 146 328 412 833 513 234 410 24 122 197
2023/20241.176 81 175 273 54 87 130 34 203 18 42 46 33
2024/20258.898 334 926 571 1.361 2.691 1.001 138 612 522 228 289 225
2025/20269.669 1.019 1.353 771 387 1.055 415 1.224 557 675 466 184 1.563
2026/20271.517 357 396 764 0 0 0 0 0 0 0 0 0
Totale 36.498